Scaling Up Cell Therapy Manufacturing
Moving Forward with an Early-on Strategy
Bioprocessing Companies Push Limits of Upstream Technologies
Goal Is to Maximize Efficiency in Bioprocess Operations
Marijuana Use in Adults Living with Sickle Cell Disease
Most States Do Not Specify Sickle Cell Disease as a Qualifying Condition for Legal Access to Marijuana
10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
Mats Boren, Ph.D.
Mats Borén, Ph.D., works as head of development at Denator.
More GEN Content From This Contributor
- Tutorials: Stabilization Method for Biological Samples
- Tutorials: Improving Molecular Distribution Analysis
- Columns: The 11 Golden Rules of Working with Proteomic Samples
- Tutorials: Improved Metabolomic Studies